This is a prospective, randomised, controlled, multicentre study to evaluate the efficacy and safety of continuous versus intermittent pyrotinib therapy in patients with human epidermal growth factor receptor (HER2)-positive advanced breast cancer.
Protocol Amendment History
1 amendment
This ClinicalTrials.gov record has been amended once since 2025-09-11.
Status change: Not Yet Recruiting → Recruiting2025-11-16